. Results of HAO1 DsiRNA screen to identify the lead HAO1 DsiRNA.
The lead HAO1 DsiRNA, HAO1-1171 was formulated in a lipid nanoparticle (LNP) to become HAO1-1, for in vivo testing. Knockdown activity of HAO1 DsiRNA oligonucleotides in HeLa cells (A) and in Hepa1-6 cells (B) were analyzed with realtime-reverse transcription-PCR. The primary screen successfully identified active DsiRNAs, many of which suppressed HAO1 mRNA to a level greater than 80 %. (C) Eight HAO1 DsiRNAs from the primary screen were selected and formulated in LNP for in vivo evaluation. Wild-type mice were injected with DsiRNAs at 0.1 or 1 mg/kg. Liver samples were collected after 24 hours for analysis of HAO1 mRNA expression. Realtime-reverse transcription-PCR analysis showed that the lead DsiRNA exhibited potent activity. Expression of Hao1 mRNA of each individual animal was plotted. The potent HAO1 DsiRNA, HAO1-1171 was then selected to become HAO1-1 for all subsequent in vivo studies. Male Agxt -/-mice were divided into 4 groups each containing 7 animals, and were supplied with either 0.7 % EG (Groups 2 to 4) or regular drinking water as a control (Group 1), as described in Figure 4 . Animals of Group 1 (water/PBS) and 2 (EG/PBS) were injected with three doses of PBS on days 0, 7, and 14. Animals of Group 3 (EG/PBS/HAO1-1) were injected with two doses of PBS on days 0 and 7 as well as a single dose of HAO1-1 on day 14. Group 4 (EG/HAO1-1) received three doses of HAO1-1 on days 0, 7, and 14. Both PBS and HAO1-1 were given intravenously. The body weight (A) and water consumption (B) were measured periodically and are shown as average values. Wild-type mice were injected with HAO1-1 monthly with 0.1 or 1 mg/kg of HAO1-1. Blood cell count and blood chemistry were analyzed monthly. In the other group of animals, a single high dose of 10 mg/kg of HAO1-1 was also injected and only for the first cycle. This group was intended to reveal potential safety issues to be watched for in chronic repeat-dosing groups receiving lower doses. Animals that received a high single administration of HAO1-1 at 10 mg/kg only exhibited transient elevations of ALT, AST and LDH, and indicated that 24 hours after dosing is the appropriate time at which to evaluate potential effects after chronic administration of HAO1-1. Results indicated that animals treated with 0.1 or 1 mg/kg HAO1-1 monthly displayed no obvious liver or kidney toxicities, compared to animals treated with PBS. 
